Barinthus Biotherapeutics plc (FRA:2AB)
Germany · Delayed Price · Currency is EUR 0.5850
+0.0200 (3.54%)
Last updated: Jun 10, 2026, 8:02 AM CET
Barinthus Biotherapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
25.58M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 14.97M | 14.17M | 1,766.46% |
| Dec 31, 2023 | 802.00K | -43.90M | -98.21% |
| Dec 31, 2022 | 44.70M | 44.44M | 16,580.22% |
| Dec 31, 2021 | 268.00K | -4.55M | -94.44% |
| Dec 31, 2020 | 4.82M | -2.02M | -29.57% |
| Dec 31, 2019 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 635.20M |
| Darwin AG | 54.30M |
| Paion AG | 14.81M |
| 2invest AG | 8.89M |
| MagForce AG | 1.08M |
| Biomark Diagnostics | 57.01K |
| co.don AG | 22.00K |
| bioXXmed AG | 20.49K |
Barinthus Biotherapeutics News
- 5 weeks ago - Barinthus Biotherapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 5 weeks ago - Barinthus Biotherapeutics Earnings release: Q1 2026 - Filings
- 5 weeks ago - Barinthus Biotherapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Barinthus Biotherapeutics Slides: Corporate presentation - Filings
- 3 months ago - Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year - TheFly
- 3 months ago - Barinthus Biotherapeutics Earnings release: Q4 2025 - Filings
- 3 months ago - Barinthus Biotherapeutics Annual report: Q4 2025 - Filings